FrancophonIA/ELRC3.0 huggingface dataset:
English: Amiodarone, dronedarone, ivabradine, quinidine, or ranolazine to treat certain heart disorders (e.g. abnormal heart rhythm)
Maltese: Amiodarone, dronedarone, ivabradine, quinidine, jew ranolazine biex titratta ċerti disturbi tal-qalb (eż. ritmu mhux normali tal-qalb)
English: H2-RECEPTOR ANTAGONISTS Cimetidine
Maltese: TAR-RIĊETTUR H2 Cimetidine
English: Phase 3 trial TMC114IFD3013 (EMERALD) evaluated the efficacy of Symtuza in virologicallysuppressed (HIV-1 RNA less than 50 copies/mL) HIV-1 infected patients.
Maltese: Il-prova TMC114IFD3013 (EMERALD) ta' Fażi 3 ivvalutat l-effikaċja ta' Symtuza f'pazjenti infettatti b'HIV-1 soppressi b'mod viroloġiku (inqas minn 50 kopja/mL RNA ta' HIV-1).
English: OESTROGEN-BASED CONTRACEPTIVES Drospirenone Ethinylestradiol (3 mg/0.02 mg once daily)
Maltese: TAL-ESTROĠENU Drospirenone Ethinylestradiol (3 mg/0.
English: DRV = darunavir; FTC = emtricitabine; PDVF = protocol-defined virologic failure; PI = protease inhibitor; RAM = resistanceassociated mutation; TDF = tenofovir disoproxil fumarate; TAF = tenofovir alafenamide
Maltese: FTC = emtricitabine; PDVF, protocol-defined virologic failure = falliment viroloġiku ddefinit mill-protokol; PI, protease inhibitor = inibitur tal-protease;
English: The combination of lurasidone, pimozide, quetiapine or sertindole and Symtuza is contraindicated (see section 4.3).
Maltese: Il-kombinazzjoni ta' lurasidone, pimozide, quetiapine jew sertindole u Symtuza hija kontraindikata (ara sezzjoni 4.3).
English: Table 1: Interactions between the individual components of Symtuza and other medicinal products
Maltese: Tabella 1: Interazzjonijiet bejn il-komponenti individwali ta' Symtuza u prodotti mediċinali oħra
English: Virologic Response, % HIV-1 RNA < 50 copies/mL
Maltese: Rispons Viroloġiku, % RNA ta' HIV-1 < 50 kopja/mL Differenza tat-trattament
English: Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine.
Maltese: Emtricitabine huwa inibitur nucleoside ta' reverse transcriptase (NRTI, nucleoside reverse transcriptase inhibitor) u nucleoside analogu ta' 2'-deoxycytidine.
English: Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Maltese: Tenofovir alafenamide jiġi ttrasportat mill-glikoproteina P (P-gp, P-glycoprotein) u mill-proteina ta' reżistenza tal-kanċer tas-sider (BCRP, breast cancer resistance protein).
English: In vivo, darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) in HIV-1 protease were derived from clinical trial data of ART-experienced patients, all of whom were protease inhibitor experienced.
Maltese: In vivo, mutazzjonijiet assoċjati ma' reżistenza għal darunavir (V11I, V32I, L33F, I47V, I50V, I54L jew M, T74P, L76V, I84V u L89V) fil-protease ta' HIV-1 inkisbu minn dejta minn provi kliniċi f'pazjenti li kienu diġà ħadu ART qabel, li kollha kemm huma kienu diġà ħadu inibitur ta' protease qabel.
English: Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate.
Maltese: Emtricitabine jiġi fosforilat permezz ta' enzimi taċ-ċelluli biex jifforma emtricitabine triphosphate.
English: Subjects with PDVF, n (%)
Maltese: evalwati għarreżistenza, n (%)
English: At Week 36 M184M/I/V observed, conferring resistance to FTC.
Maltese: F'ġimgħa 36 ġiet osservata M184M/I/V, li tagħti reżistenza għal FTC.
English: A trial of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B).
Maltese: Prova tal-farmakokinetika ta' cobicistat saret f'individwi mhux infettati b'HIV-1 b'indeboliment moderat tal-fwied (Klassi B ta' Child-Pugh).
English: Yellow to yellowish-brown capsule shaped tablet of 22 mm x 11 mm, debossed with “8121” on one side and “JG” on the other side.
Maltese: Pillola ta' lewn isfar sa isfar fil-kannella f'għamla ta' kapsula ta' 22 mm x 11 mm, imnaqqxa b'“8121” fuq naħa waħda u “JG”fuq in-naħa l-oħra.
English: Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (frequency cannot be estimated from the available data)
Maltese: Il-kategoriji ta' frekwenza huma ddefiniti kif ġej: komuni ħafna (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/1,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000) u mhux magħruf (ma tistax tittieħed stima tal-frekwenza mid-data disponibbli).
English: The 725 patients in total had a median age of 34 years (range 18-71), 88.3% were male, 83.2% White, 11.1% Black, 1.5% Asian.
Maltese: Is-725 pazjent globalment kellhom medjan ta' età ta' 34 sena (firxa minn 18-71), 88.3% kienu rġiel, 83.2% Bojod, 11.1% Suwed, 1.5% Asjatiċi.
English: Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease (KD of 4.5 x 10
Maltese: Darunavir huwa inibitur tad-dimerizzazzjoni u tal-attività katalitika tal-protease ta' HIV-1 (KD ta' 4.5 x 10
English: HIV-1 isolates with the K65R mutation have low-level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine.
Maltese: Iżolati ta' HIV-1 bil-mutazzjoni K65R għandhom suxxettibiltà mnaqqsa ta' livell baxx għal abacavir, emtricitabine, tenofovir, u lamivudine.
English: During the darunavir/ritonavir clinical development program (N = 3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir.
Maltese: Matul l-iżvilupp tal-programm kliniku ta' darunavir/ritonavir (N = 3,063), lepatite kienet irrappurtata f'0.5% tal-pazjenti li kienu qed jirċievu terapija antiretrovirali kkombinata b'darunavir/ritonavir.
English: Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human PBMCs and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL).
Maltese: Darunavir juri attività kontra razez tal-laboratorju u iżolati kliniċi ta' HIV-1 u razez tal-laboratorju ta' HIV-2 f'linji ta' ċelluli T infettati b'mod akut, f'PBMCs umani u f'monoċiti/makrofaġi umani b'valuri medjani EC50 li jvarjaw minn 1.2 sa 8.5 nM (0.7 sa 5.0 ng/mL).
English: At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults.
Maltese: Fil-ġimgħa 48, 92% (46/50) kisbu RNA ta' HIV-1 < 50 kopja/mL, li huwa simili għar-rati ta' rispons fl-istudji ta' adulti infettati b' HIV-1 li qatt ma kienu ħadu trattament qabel.
English: Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate.
Maltese: Sussegwentement tenofovir intraċellulari jiġi fosforilat fil-metabolit farmakoloġiku attiv tenofovir diphosphate.
English: (P-glycoprotein inhibition)
Maltese: (inibizzjoni tal-glikoproteina P)
English: p < 0.001 for all 4 lipid parameters when comparing D/C/F/TAF versus D/C + F/TDF at Week 48 No comparator data available beyond Week 48
Maltese: p < 0.001 għall-kull waħda mill-4 parametri tal-lipidi meta wieħed iqabbel D/C/F/TAF versus D/C + F/TDF f'Ġimgħa 48 M'hemmx data disponbbli għall-kumparatur wara Ġimgħa 48
English: Genotypic testing should guide the use of Symtuza (see sections 4.2, 4.4, and 5.1).
Maltese: Ittestjar ġenotipiku għandu jiggwida l-użu ta' Symtuza (ara sezzjonijiet 4.2, 4.4, u 5.1).
English: Virologic Outcomes in AMBER at Week 48 and 96 (FDA Snapshot) Week 48
Maltese: Riżultati viroloġiċi f'AMBER f'Ġimgħa 48 u 96 (FDA Snapshot)
English: NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE Buprenorphine/naloxone
Maltese: ANALĠEŻIĊI NARCOTIĊI/TRATTAMENT GĦAL DIPENDENZA FUQ L-OPJOJDI Buprenorphine/naloxone
English: Population pharmacokinetic analysis in HIV infected patients showed that darunavir pharmacokinetics are not considerably different in the age range (18 to 75 years) evaluated in HIV infected patients (N = 12, age ≥ 65 years) (see section 4.4).
Maltese: Analiżi farmakokinetika ta' popolazzjoni f'pazjenti infettati bl-HIV urew li l-farmakokinetika ta' darunavir ma kinitx differenti b'mod konsiderevoli fil-firxa ta' etajiet (18 sa 75 sena) evalwati f'pazjenti infettati bl-HIV (N = 12, età ≥ 65 sena) (ara sezzjoni 4.4).
English: FDA Snapshot Outcome HIV-1 RNA < 50 copies/mL Virologic Failure
Maltese: Riżultat Snapshot ta' FDA < 50 kopja/mL ta' RNA ta' HIV-1 Falliment Viroloġiku
English: • tenofovir alafenamide, an anti-HIV medicine known as a nucleotide reverse transcriptase inhibitor
Maltese: • tenofovir alafenamide, mediċina kontra l-HIVmagħrufa bħala inibitur nucleotide ta' reverse transcriptase
English: Janssen-Cilag A/S Tlf: +45 45 94 82 82 jacdk@its.jnj.com
Maltese: Danmark Janssen-Cilag A/S Tlf: +45 4594 8282 jacdk@its.jnj.com
English: There are no pharmacokinetic data on tenofovir alafenamide in patients with eGFRCG < 15 mL/min.
Maltese: Ma hemm l-ebda dejta farmakokinetika dwar tenofovir alafenamide f'pazjenti b'eGFRCG < 15 mL/min.
English: The unbound fraction was also substantially reduced, including around 90% reductions of Cmin levels.
Maltese: Il-porzjon mhux marbut ukoll tnaqqas b'mod sostanzjali, inkluż tnaqqis ta' madwar 90% fil-livelli tas-Cmin.
English: In HIV infected patients treated with CART, immune reactivation syndrome has been reported.
Maltese: F'pazjenti infettati bl-HIV ittrattati b'CART, ġie rrappurtat sindrom ta' riattivazzjoni immuni.
English: Adverse reactions are listed by system organ class (SOC) and frequency category in Table 2.
Maltese: Ir-reazzjonijiet avversi huma elenkati skont il-klassi tas-sistemi u tal-organi (SOC, system organ class) u l-kategorija ta' frekwenza f'Tabella 2.
English: Based on theoretical considerations, no clinically relevant interaction is expected.
Maltese: Abbażi ta' konsiderazzjonijiet teoretiċi, ma hija mistennija l-ebda interazzjoni klinika rilevanti.
English: Based on theoretical considerations Symtuza is expected to increase concentrations of clonazepam (inhibition of CYP3A)
Maltese: Abbażi ta' konsiderazzjonijiet teoretiċi Symtuza huwa mistenni li jżid il-konċentrazzjonijiet ta' clonazepam (inibizzjoni ta' CYP3A)
English: However,the safety of components of Symtuza was evaluated through the clinical study TMC114-C230 (N = 12) for darunavir with ritonavir and GS-US-292-0106 (N = 50) for a fixed dose combination containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
Maltese: Madankollu, is-sigurtà tal-komponenti ta' Symtuza ġiet stmata permezz tal-istudju kliniku TMC114-C230 (N = 12) għal darunavir b'ritonavir u f'GS-US-292-0106 (N = 50) għal kombinazzjoni li kien fiha elvitegravir, cobicistat, emtricitabine u tenofovir alafenamide b'doża fissa.
English: The exposure to darunavir and cobicistat administered as the Symtuza was 30-45% lower and 16-29% lower, respectively, in fasted compared to fed condition.
Maltese: L-esponiment għal darunavir u cobicistat mogħti bħala Symtuza kien 30-45% inqas u 16-29% inqas, rispettivament, meta mogħti fl-istat sajjem imqabbel mal-istat mitmugħ.
English: Treatment with darunavir/cobicistat 800/150 mg during the second and third trimester has been shown to result in low darunavir exposure, with a reduction of around 90% in Cmin levels (see section 5.2).
Maltese: It-trattament b'darunavir/cobicistat 800/150 mg matul it-tieni u t-tielet trimestru ntwera li jwassal għal esponiment baxx għal darunavir, bi tnaqqis ta' madwar 90% fil-livelli tas-Cmin (ara sezzjoni 5.2).
English: - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as an injection (medicines to treat trouble with sleeping or anxiety) - Metformin (to treat type 2 diabetes)
Maltese: - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam meta jintuża bħala injezzjoni (mediċini li jitrattaw problemi bl-irqad u/jew ansjetà) - Metformin (biex jitratta dijabete tat-tip 2)
English: Based on MH test adjusting for bPI at screening (ATV with rtv or COBI, DRV with rtv or COBI, LPV with rtv)
Maltese: Ibbażat fuq it-test MH b'aġġustament għal bPI meta sar l-iskrining (ATV b'rtv jew COBI, DRV b'rtv jew COBI, LPV b'rtv)
English: The combination may result in increased risk of cardiovascular adverse events with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Maltese: Il-kombinazzjoni tista' twassal għal żieda fir-riskju ta' avvenimenti kardjovaskulari avversi b'salmeterol, inkluż titwil tal-intervall QT, palpitazzjonijiet u takikardija tassinus.
English: Co-administration with the following medicinal products due to the potential for serious and/or life-threatening adverse reactions (see section 4.5): - alfuzosin - amiodarone, dronedarone, ivabradine, quinidine, ranolazine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - rifampicin - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - dapoxetine - domperidone - naloxegol - pimozide, quetiapine, sertindole, lurasidone (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Maltese: L-għoti flimkien ma' dawn il-prodotti mediċinali minħabba l-possibbiltà ta' reazzjonijiet avversi serji u/jew ta' periklu għall-ħajja (ara sezzjoni 4.5): - alfuzosin - amiodarone, dronedarone, ivabradine, quinidine, ranolazine - colchicine meta jintuża f'pazjenti b'indeboliment tal-kliewi u/jew tal-fwied (ara sezzjoni 4.5) - rifampicin - derivat tal-ergot (eż. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - dapoxetine - domperidone - naloxegol - pimozide, quetiapine, sertindole, lurasidone (ara sezzjoni 4.5) - triazolam, midazolam mogħtija mill-ħalq (dwar kawtela għal midazolam mogħti b'mod parenterali, ara sezzjoni 4.5) - sildenafil - meta jintuża għat-trattament ta' pressjoni għolja fl-arterji tal-pulmun, avanafil,
English: Therapeutic drug monitoring of voriconazole, posaconazole or itraconazole is recommended.
Maltese: Huwa rrakkomandat monitoraġġ terapewtiku tal-mediċina għal voriconazole, posaconazole jew itraconazole.
English: - Rifabutin (against bacterial infections) - Tadalafil, sildenafil, vardenafil (for erectile dysfunction or high blood pressure in the pulmonary circulation) - Amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone (to treat depression and anxiety) - Perphenazine, risperidone, thioridazine (psychiatric medicines) - Ciclosporin, everolimus, tacrolimus, sirolimus (for dampening down your immune system) as the therapeutic effect or side effects of these medicines might be increased.
Maltese: - Rifabutin (kontra infezzjonijiet bil-batterji) - Tadalafil, sildenafil, vardenafil (għal impotenza jew pressjoni għolja fiċ-ċirkolazzjoni tal pulmuni) - Amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone (biex jittrattaw depressjoni u ansjetà) - Perphenazine, risperidone, thioridazine (mediċini psikjatriċi) - Ciclosporin, everolimus, tacrolimus, sirolimus (biex jikkontrollaw is-sistema immuni tiegħek)
English: In the Phase 3 study TMC114FD2HTX3001in treatment-naïve patients, Symtuza was associated with no or smaller reductions in bone mineral density (BMD) compared DRV/COBI+F/TDF as measured by DXA analysis of hip (LS means percent change: 0.17% vs -2.69%, p < 0.001) and lumbar spine (LS means percent change: -0.68% vs -2.38%, p =0.004) after 48 weeks of treatment.
Maltese: Fl-istudju tal-Fażi 3 TMC114FD2HTX3001 f'pazjenti li qatt ma kienu ħadu trattament qabel, Symtuza ma kien assoċjat ma l-ebda tnaqqis jew inqas tnaqqis fid-densita minerali tal-għadam (BMD, bone mineral density) meta mqabbel ma' DRV/COBI+F/TDF imkejjel permezz ta' analiżi DXA tal-għadma tal-ġenbejn (LS ifisser bidla perċentwali: 0.17% vs -2.69%, p < 0.001) u tas-sinsla lumbari (LS ifisser bidla perċentwali: -0.68% vs -2.38%, p =0.
English: Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.
Maltese: Suxxettibiltà mnaqqsa għal emtricitabine hija assoċjata ma' mutazzjonijiet M184V/I fl-RT ta' HIV-1.
English: • cobicistat, a booster (enhancer) of darunavir
Maltese: • cobicistat, sustanza li ssaħħah lil darunavir
English: Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infection, combinations ATC code: J05AR22
Maltese: Antivirali għal użu sistemiku; antivirali għat-trattament ta' infezzjonijiet tal-HIV, kombinazzjonijiet Kodiċi ATC:
English: Co-administration of amiodarone, dronedarone, ivabradine, quinidine, or ranolazine and Symtuza is contraindicated (see section 4.3).
Maltese: L-għoti ta' amiodarone, dronedarone, ivabradine, quinidine, jew ranolazine flimkien ma' Symtuza huwa kontraindikat (ara sezzjoni 4.3).
English: The overall safety profile of Symtuza is based on data from a randomised, double-blinded, comparative Phase 2 trial, GS-US-299-0102 (N = 103 on darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), data from 2 Phase 3 trials TMC114FD2HTX3001 (AMBER, N = 362 on D/C/F/TAF) and TMC114IFD3013 (EMERALD, N = 763 on D/C/F/TAF), and on all available clinical trial and post-marketing data of its components.
Maltese: 2 GS-US-299-0102 (N = 103 fuq darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) fejn la l-investigaturi u lanqas l-individwi li ntagħżlu b'mod arbitrarju ma kienu jafu liema sustanza qed tintuża, data minn 2 provi ta' Fażi 3 TMC114FD2HTX3001 (AMBER, N = 362 fuq D/C/F/TAF) u TMC114IFD3013 (EMERALD, N = 763 fuq D/C/F/TAF), u fuq id-dejta kollha disponibbli minn provi kliniċi u wara t-tqegħid fis-suq tal-komponenti ta' Symtuza.
English: The use of Symtuza in ART-naïve adolescent patients from the age of 12 years to < 18 years, and weighing at least 40 kg is supported by two trials in HIV-1 infected paediatric patients (TMC114-C230 and GS-US-292-0106).
Maltese: L-użu ta' Symtuza f'pazjenti adolexxenti li qatt ma kienu ħadu ART qabel mill-età ta' 12-il sena sa < 18-il sena, u li jiżnu mill-anqas 40 kg huwa sostnut minn żewġ provi f'pazjenti pedjatriċi infettati blHIV-1 (TMC114-C230 u GS-US-292-0106).
English: Using Cyst C as filtration marker, the median changes in estimated glomerular filtration rate calculated using the CKD-EPI (eGFRCKD-EPI CystC) formula were respectively 4.0 mL/min/1.73 m² and 1.6 mL/min/1.73 m² (p<0.001).
Maltese: Bl-użu ta' Cyst C bħala markatur ta' filtrazzjoni, il-medjan tal-bidliet flistima tar-rata ta' filtrazzjoni glomerulari kkalkulata bl-użu tal-formula CKD-EPI (eGFRCKD-EPI CystC) kien 4.0 mL/min/1.73 m² u 1.6 mL/min/1.73 m² (p<0.001).
English: The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).
Maltese: Il-bijotrasformazzjoni ta' emtricitabine tinkludi l-ossidazzjoni tal-parti attiva thiol biex jiġu ffurmati d-dijasterjomeri 3'-sulphoxide (madwar 9% tad-doża) u l-konjugazzjoni ma' glucuronic acid biex jiġi ffurmat 2'-O-glucuronide (madwar 4% tad-doża).
English: A trial of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with severe renal impairment (eGFRCG below 30 mL/min).
Maltese: Prova tal-farmakokinetika ta' cobicistat saret f'individwi mhux infettati bl-HIV-1 b'indeboliment sever tal-kliewi (eGFRCG inqas minn 30 mL/min).
English: Name and address of the manufacturer(s) responsible for batch release Janssen-Cilag SpA
Maltese: Isem u indirizz tal-manifattur(i) responsabbli għall-ħruġ tal-lott Janssen-Cilag SpA
English: Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
Maltese: Linibizzjoni tal-metaboliżmu medjat minn CYP3A permezz ta' cobicistat ittejjeb l-esponiment sistemiku ta' sustrati ta' CYP3A, bħal darunavir, fejn il-bijodisponibilità hi limitata u l-half-life tiqsar minħabba metaboliżmu li jiddependi minn CYP3A.
English: • symptoms of infection or of autoimmune disorders (immune reconstitution inflammatory syndrome)
Maltese: • sintomi ta' infezzjoni jew ta' disturbi awtoimmuni (sindrome infjammatorju ta' rikostituzzjoni immuni)
English: In vitro studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes.
Maltese: Studji in vitro wrew li tenofovir alafenamide jiġi metabolizzat għal tenofovir (metabolit maġġuri) minn cathepsin A f'PBMCs (inklużi limfoċiti u ċelluli oħrajn filmira tal-HIV) u makrofaġi; u minn carboxylesterase-1 fl-epatoċiti.
English: The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs.
Maltese: L-attività antivirali ta' emtricitabine kontra l-iżolati kliniċi u tal-laboratorju ta' HIV-1 ġiet stmata f'linji ta' ċelluli limfoblastojd, fil-linja ta' ċelluli MAGI CCR5, u fil-PBMCs.
English: - Fentanyl, oxycodone, tramadol (to treat pain).
Maltese: - Fentanyl, oxycodone, tramadol (biex jitrattaw l-uġigħ).
English: The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM).
Maltese: Il-valuri EC50 għal tenofovir alafenamide kienu jvarjaw minn 2.0 sa 14.7 nM. Tenofovir alafenamide wera attività antivirali f'koltura ta' ċelluli kontra l-gruppi kollha (M, N, u O) ta' HIV-1, inkluż is-sottotipi A, B, C, D, E, F, u G (il-valuri EC50 kienu jvarjaw minn 0.10 sa 12.0 nM) u wrew attività speċifika għar-razza kontra
English: DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens-Johnson syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported.
Maltese: DRESS (Raxx mill-Mediċina b'Eosinifilja u Sintomi Sistemiċi, Drug Rash with Eosinophilia and Systemic Symptoms) u sindrom ta' Stevens-Johnson ġew irrappurtati b'mod rari (< 0.1%), u waqt l-esperjenza ta' wara t-tqegħid fis-suq ġew irrappurtati nekroliżi tossika tal-epidermide u pustullożi eksantematuża akuta mifruxa.
English: The combination of avanafil and Symtuza is contraindicated (see section 4.3).
Maltese: Il-kombinazzjoni ta' avanafil u Symtuza hija kontraindikata (ara sezzjoni 4.3).
English: The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+-T lymphocytes.
Maltese: L-attività antivirali ta' tenofovir alafenamide kontra iżolati tal-laboratorju u iżolati kliniċi tassottotip B ta' HIV-1 ġiet stmata f'linji ta' ċelluli limfoblastojd, f'PBMCs, f'ċelluli monoċiti/makrofaġi primarji u f'limfoċiti T CD4+.
English: Carbamazepine, phenobarbital and phenytoin to prevent seizures Colchicine (if you have kidney/liver problems) to treat gout The combination product lopinavir/ritonavir anti-HIV medicine
Maltese: Carbamazepine, phenobarbital u phenytoin biex tevita aċċessjonijiet Colchicine (jekk għandek problemi talkliewi/tal-fwied)
English: After 96 weeks of treatment with Symtuza, the (95% CI) percent changes from baseline in BMD at the hip and spine region were respectively: -0.26 (-0.96; 0.45) % and -0.93 (-1.82; -0.05) %.
Maltese: Wara 96 ġimgħa ta' trattament b'Symtuza, il-bidliet perċentwali (95% CI) mil-linja bażi fil-BMD fil-parti tal-ġenbejn u tas-sinsla tad-dahar kienu rispettivament: -0.26 (-0.96; 0.45) % u -0.93 (-1.82; -0.05) %.